Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 8/20 | 0.49 |
| ▸ | FGFR4 | P22455 | 5/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | LYN | P07948 | 3/20 | 0.42 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
| ▸ | CCND2 | P30279 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23314878 | 0.85 | FGFR4 (0.67) | FGFR1FGFR4FGFR2FGFR3SRC | |
| SCHEMBL661106 | 0.83 | RIPK2 (0.49) | FGFR1LYNSRCBTKRIPK2 | |
| SCHEMBL28648564 | 0.82 | FGFR1 (0.53) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL4713056 | 0.80 | FGFR4 (0.51) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL16193568 | 0.80 | RIPK2 (0.43) | FGFR1LYNSRCBTKRIPK2 | |
| SCHEMBL16245982 | 0.79 | FGFR1 (0.49) | FGFR1BTK | |
| SCHEMBL5266722 | 0.79 | FGFR1 (0.35) | FGFR1FGFR4FGFR2FGFR3LYN | |
| SCHEMBL4713077 | 0.78 | FGFR1 (0.56) | FGFR1FGFR4FGFR2FGFR3KDR | |
| SCHEMBL4563490 | 0.77 | GAK (0.39) | FGFR1FGFR4KDRLYNSRC | |
| SCHEMBL16246159 | 0.77 | FGFR1 (0.51) | FGFR1FGFR4FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307450-B1 | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido(2,3-d)pyrimidin-7-ones | WARNER LAMBERT CO (US) | 2008-09-17 | — | — | EP | disclosed |
| US-7022711-B2 | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2006-04-04 | — | — | US | disclosed |
| US-6960662-B2 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20030220345-A1 | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones | HAMBY JAMES MARINO (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030216415-A1 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones | BEYLIN VLADIMIR GENUKH (US) | 2003-11-20 | — | — | US | disclosed |
| EP-1307450-A2 | 2-(4-PYRDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO(2.3-D)PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002012238-A2 | 2-(4-PYRIDYL)AMINO-6-DIALKOXYPHENYL-PYRIDO[2,3-d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY (US) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216415-A1 | Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones | DPYD, PDXK, PARP2 | FGFR1 2394/4885FGFR4 1740/4885FGFR2 1155/4885 |
| US-20030220345-A1 | 2-(4-Pyridyl)amino-6-dialkoxyphenyl-pyrido[2,3-d]pyrimdin-7-ones | FLT1, FLT4, MKI67 | FGFR1 196/4885FGFR4 213/4885FGFR2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.